UBS Warburg Remains Upbeat on Medtronic
Medtronic (MDT ) posted $0.30 Q4 EPS from operations on a 6% sales rise. UBS Warburg trimmed its estimate and lowered its price target on the medical device maker, but reiterated its strong buy rating on the shares.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.